Neurotech International Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Anthony Filippis

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2.6yrs
Board average tenure	6yrs

Recent management updates

Recent updates

Here's Why We're A Bit Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Mar 05

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Oct 14

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Jul 01

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Jan 21

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Oct 06

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

May 18

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Dec 21

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 04

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Dec 08

CEO

Anthony Filippis

less than a year

Tenure

Dr. Anthony Filippis, BSc (Hons.), PhD, MBA, serves as Managing Director, CEO and Director at Neurotech International Limited since February 01, 2025. He serves as Chief Operating Officer at Percheron Ther...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Alexandra Andrews	Chief Operating Officer	2.6yrs	AU$36.51k	no data
Gerald Quigley	Director of Public Relations & Director	2.7yrs	AU$136.55k	0.027% A$ 8.3k
Anthony Filippis	MD, CEO & Director	less than a year	no data	no data
Emanuela Russo	Chief Scientific Officer & Member of Scientific Advisory Board	6.5yrs	no data	no data
Carolyn Ellaway	Chief Medical Officer	less than a year	no data	no data
Peter James Griffiths	Chief Executive Officer of AAT Research Ltd	4.5yrs	AU$109.03k	no data
Alessandra Gauvin	Company Secretary	no data	no data	no data

2.6yrs

Average Tenure

Experienced Management: NTI's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gerald Quigley	Director of Public Relations & Director	2.8yrs	AU$136.55k	0.027% A$ 8.3k
Anthony Filippis	MD, CEO & Director	less than a year	no data	no data
Emanuela Russo	Chief Scientific Officer & Member of Scientific Advisory Board	no data	no data	no data
Evian Gordon	Member of Scientific Advisory Board	6.5yrs	no data	no data
Robert Johnston	Director	1yr	AU$34.05k	0.099% A$ 31.0k
Mark Davies	Independent Non-Executive Chairman	6yrs	AU$61.22k	1.13% A$ 353.8k
David Cantor	Chairman of Scientific Advisory Board (Currently Dormant)	8.3yrs	AU$34.71k	no data
Tanju Surmeli	Member of Scientific Advisory Board	6.5yrs	no data	no data

6.0yrs

Average Tenure

Experienced Board: NTI's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/13 23:20
End of Day Share Price	2025/04/11 00:00
Earnings	2024/12/31
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurotech International Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew Goodsall	MST Financial Services Pty Limited

Neurotech International Management

Management criteria checks 2/4

Key information

Recent management updates

Thomas Duthy Resigns as an Executive Director of Neurotech International Limited

Neurotech International Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Less than half of directors are independent

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Recent updates

New minor risk - Share price stability

Thomas Duthy Resigns as an Executive Director of Neurotech International Limited

Here's Why We're A Bit Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

New major risk - Financial position

New major risk - Revenue and earnings growth

Neurotech International Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

New minor risk - Share price stability

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Neurotech International Limited Announces Nti164 Clinical Program Update

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains